Altimmune 2025 Q2 Earnings Improved Net Loss

Altimmune reported its Q2 2025 earnings on August 12, 2025, with stable total revenue at $5000, consistent with the same period in 2024. The company narrowed its net loss significantly, reflecting progress in cost management and operational efficiency. This report highlights the key financial metrics and strategic developments.

Altimmune reported its fiscal 2025 Q2 earnings on Aug 12th, 2025. The total revenue of Altimmune remained stable at $5000 in 2025 Q2 with no significant change from 2024 Q2, with specific segment revenue listed as follow: Research grants: $5000 and Total: $5000. This shows that all revenue is derived from research grants, indicating a singular revenue stream.

Altimmune narrowed losses to $0.27 per share in 2025 Q2 from a loss of $0.35 per share in 2024 Q2 (22.9% improvement). Meanwhile, the company successfully narrowed its net loss to $-22.15 million in 2025 Q2, reducing losses by 10.1% compared to the $-24.64 million net loss reported in 2024 Q2. This improvement in net income is a positive indicator of the company’s ability to manage its expenses and improve profitability.

The stock price of Altimmune has climbed 3.13% during the latest trading day, has edged down 1.36% during the most recent full trading week, and has tumbled 12.56% month-to-date.

The strategy of buying Altimmune (ALT) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in a significant underperformance. Over the past three years, the strategy delivered an 81.14% loss, compared to a 46.32% gain for the benchmark. The excess return was -127.46%, and the strategy's CAGR was -43.78%. Additionally, the strategy had a maximum drawdown of 0.00% and a Sharpe ratio of -0.38, indicating a high risk and a negative return relative to the benchmark.

Vipin K. Garg, Ph.D., President and Chief Executive Officer, highlighted the positive 24-week results from the IMPACT Phase 2b trial, noting pemvidutide demonstrated statistically significant MASH resolution and weight loss, with strong safety and tolerability. He emphasized the preparation for an End-of-Phase 2 Meeting with the FDA in Q4 2025, which will support Phase 3 development. Garg expressed optimism about the upcoming 48-week data expected in Q4 and continued progress on pemvidutide, underscoring the company’s strategic focus on advancing this candidate as a potential differentiated therapy.

The company expects to hold an End-of-Phase 2 Meeting with the FDA in Q4 2025 and anticipates reporting full 48-week data from the IMPACT trial in the same quarter. Pemvidutide’s Phase 2b trial results suggest a trajectory of continued weight loss beyond 24 weeks. The company also expects to provide further updates as it advances the candidate toward Phase 3 development in MASH.

Additional News

Within the three weeks following Altimmune's Q2 2025 earnings report, there was no direct merger or acquisition activity involving Altimmune. However, notable company developments included updates on its clinical trial progress for pemvidutide, which demonstrated encouraging results in the IMPACT Phase 2b trial. CEO Vipin K. Garg emphasized the company's strategic focus on advancing pemvidutide as a potential differentiated therapy in the treatment of MASH, with plans to hold an End-of-Phase 2 Meeting with the FDA in Q4 2025. These developments reflect the company's ongoing commitment to innovation and growth in its core therapeutic areas. There were no new dividend or stock buyback announcements related to Altimmune during this period.